● pepmg Research Desk · Peer-reviewed evidence review
What the research says about humanin
A neutral summary of the peer-reviewed literature on humanin, a small mitochondrial-derived peptide studied for cytoprotection in cell and animal models, with human evidence limited to observational and genetic associations. Research use only.
Limited evidence — Early or small human data, or strong preclinical work. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- Humanin is a 24-amino-acid mitochondrial-derived peptide (MDP), first identified from Alzheimer's-disease brain tissue, that acts as a cytoprotective, anti-apoptotic signal through a cell-surface receptor [1][2].
- In cell and animal models it protects neurons from Alzheimer-related toxicity and preserves cell viability under stress; much of the administration work uses the more stable analog HNG ([Gly14]-humanin) [1][2][7].
- Human evidence is observational: circulating humanin levels have been studied as a biomarker of cardiovascular risk, and specific humanin gene variants are associated with longevity, but no controlled human trial of humanin administration appears in this corpus [5][6].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What humanin is
Humanin is described in the literature as a short peptide of 24 amino acid residues, encoded within mitochondrial DNA and belonging to a family called mitochondrial-derived peptides (MDPs), which also includes MOTS-c [1][4]. It was discovered through its ability to suppress neuronal cell death caused by Alzheimer's-disease insults, including amyloid-beta peptides and familial-Alzheimer's genes, and it protects both neuronal and non-neuronal cells from that toxicity [1]. More broadly, reviews describe humanin as a mediator of cellular stress resistance [3].
Mechanistically, reviews describe humanin acting from outside the cell by binding a cell-surface receptor related to the interleukin-6 receptor family, triggering intracellular signaling that promotes cell survival [2]. Its plasma levels are reported to be inversely correlated with growth hormone and IGF-1, tying it into the broader biology of aging [4]. Humanin has never been an approved medicine; material sold by research-chemical vendors is not an approved pharmaceutical product and is offered for laboratory and research use only.
What the research has measured
Limited evidenceThe therapeutic-style evidence is preclinical. In cell and animal studies, humanin protected neurons from Alzheimer-related death, and work in murine Alzheimer's models, including familial-Alzheimer's transgenic mice, reported that humanin reduced Alzheimer-related neuronal dysfunction in vivo [1][2]. Reviews also describe cytoprotective actions beyond the brain, such as preserving endothelial-cell function in a mouse model of atherosclerosis [4]. Because native humanin is short-lived, much administration work uses a potent analog, HNG ([Gly14]-humanin): for example, a study in a mouse model of chemotherapy-induced oligoasthenozoospermia reported that HNG improved sperm and testicular measures [7]. That record is MeSH-indexed as human because it concerns a human infertility condition, but the experiment was conducted in mice.
The human evidence is observational rather than interventional. A prospective observational study measured circulating humanin as a prognostic marker for cardiovascular events and mortality in patients on chronic hemodialysis [5]. On the genetics side, a specific humanin variant (P3S) was found enriched in centenarians carrying the APOE4 allele and linked to cognitive resilience, then explored in an APOE4 mouse model [6]. These studies associate naturally occurring humanin, or humanin gene variants, with outcomes; they do not test administering humanin to people.
In short, the corpus shows a well-described cytoprotective peptide with consistent preclinical activity and real human association data, but no controlled human trial of humanin (or HNG) administration measuring a clinical outcome.
What the studies report on safety and adverse events
Limited evidenceBecause there are no controlled human administration trials of humanin in this corpus, there is no controlled human safety or adverse-event data to report. The cell and animal studies are oriented toward mechanism and efficacy endpoints, not systematic safety characterization in humans.
One conceptual caution appears in the literature itself. Although humanin and other MDPs are widely framed as anti-aging and cytoprotective, that framing rests substantially on correlative studies, and a review specifically titled around mitochondrial-derived peptides exacerbating senescence signals that the effects of these peptides are not uniformly beneficial and depend on context [4]. This is a reminder that a cytoprotective signal in one setting is not automatically protective everywhere.
None of this is a safety guarantee. Humanin is an experimental peptide with no controlled human evaluation here, and research-chemical material is not manufactured to pharmacy standards. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
The evidence base is characterized as limited. Humanin has a clear molecular identity and a consistent body of preclinical work showing cytoprotective and neuroprotective activity in cells and animal models [1][2][4], and there is genuine human data, but that human data is observational and genetic, associating endogenous humanin or its variants with cardiovascular and longevity outcomes [5][6]. What is missing is any controlled trial of administering humanin to people.
"Limited" here means exactly that: promising and well-characterized mechanistically, supported by human association studies, but not established by human administration trials for any use. Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 7
- Humanin: after the discovery.
- Humanin and the receptors for humanin.
- The emerging role of the mitochondrial-derived peptide humanin in stress resistance.
- Mitochondrial-Derived Peptides Exacerbate Senescence.
- Unbalanced circulating Humanin levels and cardiovascular risk in chronic hemodialysis patients.
- Humanin variant P3S is associated with longevity in APOE4 carriers and resists amyloid pathology.
- Oligoasthenozoospermia is alleviated in a mouse model by [Gly14]-humanin-mediated mechanisms.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.